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Surgical site infections (SSI) substantially increase costs for healthcare pro-
viders because of additional treatments and extended patient recovery. The
objective of this study was to assess the cost and health-related quality of life
impact of SSI, from the perspective of a large teaching hospital in England.
Data were available for 144 participants undergoing clean or clean-
contaminated vascular surgery. SSI development, length of hospital stay,
readmission, and antibiotic use were recorded over a 30-day period. Patient-
reported EQ-5D scores were obtained at baseline, day 7 and day 30. Linear
regressions were used to control for confounding variables. A mean SSI-
associated length of stay of 9.72 days resulted in an additional cost of £3776
per patient (including a mean antibiotic cost of £532). Adjusting for age,
smoking status, and procedure type, SSI was associated with a 92% increase in
length of stay (P < 0.001). The adjusted episode cost was £3040. SSI reduced
patient utility between baseline and day 30 by 0.156 (P = 0.236). Readmission
rates were higher with SSI (P = 0.017), and the rate to return to work within
90 days was lower. Therefore, strategies to reduce the risk of surgical site infec-
tion for high-risk vascular patients should be investigated.
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1 | INTRODUCTION
In the UK, surgical site infection (SSI) accounts for up to
1 in 7 hospital acquired infections.1 Within vascular sur-
gery, SSI may complicate up to 40% of procedures, with
those undergoing lower limb revascularisation and major
limb amputations at the highest risk.2-4 This elevated inci-
dence is thought to relate to the high rates of co-
morbidities in vascular patients, such as diabetes, obesity,
increasing age, malnutrition, and tobacco smoking as well
as the presence of existing infection/bacteraemia.5 Further-
more, operative factors such as groin site surgery, use of
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prostheses, and long surgical procedures contribute to an
increased incidence rate of SSI.5 The consequences of SSI
in vascular surgery may be serious, with 30% to 40% of SSI
in lower limb bypass procedures resulting in a major
amputation.6 On an individual basis, SSI may cause signifi-
cant physical or psychological disability.7 On a population
basis, the costs attributed to SSI may be significant, with
an estimated cost of £700 million per annum to the
National Health Service (NHS) in the UK.8
Previous studies have reported estimates of the addi-
tional healthcare costs associated with SSI in the NHS.
Jenks et al9 report SSI rates for a range of specialties at a
large NHS hospital between April 2010 and March 2012.
For vascular surgery, the median excess postoperative
length of stay (LOS) associated with SSI was 10 days, and
the average cost was £2480 per episode at 2012 prices
(£2702 at 2018/19 prices). Coello et al10 analysed national
surveillance data from 140 English hospitals in the period
October 1997 to June 2001 for a range of surgical proce-
dures. For vascular surgery, the mean excess LOS associ-
ated with SSI was 12.2 days (95% CI 9.8-15.0) and the cost
was £3545 per episode at 2003 prices (£3862 at 2018/19
prices). These studies are now quite dated and there is a
need to validate results in light of contemporary practice.
A pilot randomised controlled trial (RCT) was con-
ducted to examine the use of post-operative dressings
coated with dialkylcarbamoyl chloride (DACC) in the
prevention of SSI in primarily closed incisional wounds.11
The study recruited patients undergoing clean or clean-
contaminated vascular surgery. The primary clinical out-
come was SSI at 30 days. A 36.9% relative risk reduction
was observed in the DACC-coated arm. Overall, the SSI
rate across both arms of the trial was 21%. Given the sig-
nificant morbidity and mortality attached to SSI follow-
ing vascular surgery as well as the burden on healthcare
service providers, it is important to quantify the clinical
and economic impact of these infections.
The aim of the current study is twofold. Firstly, to use
information from the trial to estimate the cost associated
with the development of SSI in relation to length of stay
(LOS) and antibiotic treatments. Secondly, to use the same
data to assess the relationship between the development of
SSI and health-related quality of life (HRQoL). In addition,
the study considers the impact of developing SSI on both
readmission rates and on patients returning to work.
2 | METHODS
Data from 144 patients treated in a tertiary vascular sur-
gery unit in the United Kingdom were collected to deter-
mine the impact of DACC-coated dressings on the
incidence of SSI.11 This study was conducted according to
a previously published protocol.12 Ethical approval was
obtained (16/LO/2135), and the study conduct was in
accordance with the Declaration of Helsinki.13 The study
was prospectively registered with http://clinicaltrials.gov
(NCT02992951). Participants were randomised to postoper-
ative wound dressing with either a DACC-coated occlusive
absorbent dressing or a non DACC-coated occlusive absor-
bent dressing in a 1:1 ratio. Randomisation occurred in the
theatre after wound closure to prevent performance bias.
The ASEPSIS scoring system was used to assess the wound
between postoperative days 5 and 7 and at postoperative
day 30 ± 3 days. For further details on data collection
methods for the primary outcomes see Totty et al.11 During
the study, data were also collected on a series of secondary
outcomes, including antibiotic use, LOS, time taken to
return to work, and readmission to hospital. At each study
follow-up time point, patient-reported HRQoL was
recorded using the EQ-5D-3L instrument.14
2.1 | Data analysis
Eight of the 144 records were removed prior to data anal-
ysis for the following reasons:
• Participant withdrew from the study (n = 4)
• No follow-up data after day 0 (n = 2)
• Incorrect follow-up dates recorded, resulting in
returning to work prior to surgery occurring (n = 1)
• SSI reported but no antibiotic treatment information
recorded (n = 1)
These records were not excluded from the primary
outcomes analysis which focused on the feasibility of
conducting a full RCT.11 A final total of 136 patients were
Key Messages
• Surgical site infections (SSI) in vascular surgery
can result in serious consequences on both
individual and population basis
• Data from 144 patients treated in a tertiary vas-
cular surgery were used to analyse the effects of
SSI. All statistical analyses were performed in R
v 3.6.0
• SSI reduce patient health-state utility and have
a considerable cost impact for hospital pro-
viders through increased length of stay,
readmission, and the costs of antibiotics
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available for this analysis. Study participants were strati-
fied into those who did not experience SSI within 30 days
following surgery (No SSI; n = 107) and those who did
(SSI; n = 29).
Complete EQ-5D records were available at baseline
for 73 patients who did not develop SSI and 18 patients
who did. At day 30, there were 52 and 9 complete records
for patients with no SSI and with SSI, respectively.
Linear models were estimated to control for the
impact of multiple independent variables on the average
LOS, HRQoL at baseline, and at days 7 and 30. Initial sta-
tistical model development found that using a natural
logarithmic transformation of the LOS data [ln(LOS
+ 1)] resulted in a superior model fit (confirmed by
Akaike information criterion (AIC) values and graphi-
cally; not presented).
The variables SSI within 30 days, age, sex, body mass
index (BMI), smoking status, diabetes, and procedure
type were controlled for in the linear model for LOS.
Stepwise selection was used to find a subset of variables
that resulted in the best-performing model based on AIC.
The variables sex, BMI, and diabetes were found to have
no significant impact on LOS and therefore removed
from the final linear model (stepwise procedure; not pres-
ented). The treatment variable, standard or DACC dress-
ing, was controlled for in the linear models for HRQoL
but was found to be non-significant and was removed
during model refinement from all the linear models for
HRQoL. The covariables used in the final statistical
models are outlined in Supplementary Table S1. No
second-order interactions were considered in the statisti-
cal models because of small patient numbers. For all sta-
tistical analysis, significance was defined as P ≤ 0.05.
All statistical analyses were performed in R v 3.6.0.15
Utility values were calculated from the EQ-5D-3L instru-
ment using the UK value set with the R package eq5d
v0.7.0.16
2.2 | Cost analysis
The cost per SSI episode was estimated by adding the
inpatient cost (mean additional LOS × cost per day) to
the average cost of antibiotics. The cost per inpatient day
was calculated from a weighted average of two HRG
codes (WHO7C and WHO7D) relating to hospitalisation
associated with infection or complications of procedures.
Costs were sourced from the 2017/18 NHS Reference
Costs17 and inflated to 2018/19 prices18 (Table 1). One
record had missing data for antibiotic usage and was not
included in the cost analysis. This resulted in 28 out of
29 patients in the SSI group who were eligible for
weighted cost analysis. Antibiotic costs were calculated
as a mean cost per patient for antibiotics prescribed dur-
ing the study with relevant prices sourced from the
BNF.19
The effect of LOS on the SSI episode cost was tested
in a sensitivity analysis by applying the 95% confidence
interval around the unadjusted mean LOS, median LOS,
and the mean LOS adjusted for the effects of SSI within
30 days, age, smoking status, and procedure type.
3 | RESULTS
Baseline characteristics for the 136 patients included in
the analysis are summarised in Table 2. There are no sta-
tistically significant differences between groups (SSI vs
non-SSI) in age (mean 63.6 vs 62.6 years; P = 0.698), sex
(males: 79.3% vs 63.6%; P = 0.168), or BMI (mean 27.33
vs 28.71; P = 0.248). However, there are statistically sig-
nificant differences in smoking status and diabetes. There
are relatively more current smokers in the SSI group
(P = 0.002) and relatively fewer patients with diabetes
(P = 0.035). There are also significant differences in the
type of surgical procedure (P = 0.031) (Table 2).
3.1 | Length of stay
The mean LOS including readmission was 6.52 days
(no SSI, n = 107) and 16.24 days (SSI, n = 29), a differ-
ence of 9.72 days (95% CI 5.25-14.18). The median length
of stay was 4 days (no SSI) and 11 days (SSI), a difference
of 7 days. After controlling for differences in age,
smoking status, and procedure type, the presence of SSI
TABLE 1 Cost of an additional hospitalisation because of infection or other complication per day
Currency Code Description Activity Unit Cost
WH07C Infection or other complication of procedures, with single
intervention, with CC score 2+
1463 £339.23
WHO7D Infection or other complication of procedures, with single
intervention, with CC score 0-1
2888 £330.99
Weighted average £333.76
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TABLE 2 Baseline patient characteristics
Characteristic
Patients with no SSI
within 30 days (n = 107)
Patients with SSI
within 30 days (n = 29) P Value
Age, years (mean (SD)) 62.61 (12.74) 63.62 (11.28) 0.698
Sex, male (%) 63.6 79.3 0.168
BMI (mean (SD)) 27.33 (5.44) 28.71 (6.51) 0.248






Diet controlled 1.9 6.9
Tablet controlled 13.1 13.8
Insulin controlled 10.3 27.6
Procedure type (%) 0.031
Open surgery on the aorta/ileac vessels 23.4 3.4
Lower limb arterial surgery 35.5 55.2
Varicose vein surgery 8.4 10.3
Major limb amputation 8.4 20.7
Renal dialysis access 14.0 6.9
Other 10.3 3.4
FIGURE 1 Linear model predicted effect of SSI on the length of stay in hospital. Mean length of stay (LOS) in patients with SSI or no
SSI within 30 days of surgery was assessed using a linear model. Model coefficients for the final linear model are presented in
Supplementary Table S2. The results show that those with an SSI with 30 days of surgery have a significantly longer LOS compared with
those without an SSI (P < 0.001). The data are presented as the mean ± 95% confidence interval from 107 and 29 individual patients. The
model prediction was generated considering a patient aged 62.8 years old, who had never smoked and who had open surgery on the aorta/
ileac vessels
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at 30 days was associated with a statistically significant
92% increase in LOS (7.52 days; P < 0.001; result on the
untransformed scale; Figure 1). Model coefficients are
displayed in Supplementary Table S2.
3.2 | SSI episode cost
The weighted cost of hospitalisation because of infection or
other complication in the NHS is £333.76 per day (Table 1).
Assuming the SSI-associated LOS is the difference in mean
LOS between the two groups, the estimated inpatient cost
for an episode of SSI is £3244 (£333.76 * 9.72 days). The
mean cost of antibiotic treatment for SSI was £532. Adding
this to the inpatient cost gives an estimate of the total cost
of £3776 per episode. However, it should be noted that the
costs of antibiotics are heavily skewed. The median antibi-
otic cost per patient is £10.72 (IQR: £2.69-£119.73) but five
patients account for 94% of the total antibiotic costs, and
two patients had antibiotic costs in excess of £4000 each (see
Supplementary Table S3 for all patient antibiotic costs). The
SSI-associated LOS adjusted for age, smoking status and
procedure type was 7.52 days, and the adjusted episode cost
including antibiotics was £3040.
TABLE 3 Sensitivity analysis
Method Estimated Difference in LOS
Estimated SSI Episode Costa
Mean Lower 95% CIb Upper 95% CI
Mean 9.72 £3776 £2064 £5488
Median 7.00 £2868 £1533 £3870
Adjusted meanc 7.52 £3040 £2038 £4696
Abbreviations: CI: confidence interval; LOS, length of stay; SSI, surgical site infection.
aA constant antibiotic cost of £532 was assumed.
bLower and upper interquartile range used for the median estimate.
cBased on predictions derived from the linear model with procedure type set to “open surgery on the aorta/ileac vessels”.
FIGURE 2 Linear model predicted effect of SSI on utility at baseline, day 7 and day 30. Mean utility in patients with SSI or no SSI
within 30 days of surgery was assessed using a linear model at days 0, 7 and 30. Model coefficients for the final linear models are presented
in Supplementary Table S4. The results show a non-significant trend of reduction in utility score over time in those with SSI compared with
those without SSI. The data are presented as the mean ± 95% confidence interval from 73 and 18 individual patients at baseline, 59 and
8 individual patients at day 7 and 52 and 9 individual patients at day 30. The model predictions were generated using the mean baseline
utility for day 7 and day 30 predictions
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As a sensitivity analysis the mean additional LOS
(9.72 days), the median additional LOS (7.00 days) and
the mean adjusted additional LOS (7.52 days) were varied
within their respective 95% confidence intervals. The
mean cost of antibiotics was not changed. Episode cost
estimates range from £1533 to £5488 (Table 3).
3.3 | Health-related quality of life
Baseline utility scores for patients in the two groups were
similar (0.54 and 0.51 in the no SSI and SSI group respec-
tively; P = 0.747). Mean utility scores at day 7 and day
30 were 0.56 (no SSI) vs 0.47 (SSI), and 0.68 (no SSI) vs
0.51 (SSI), respectively (Figure 2). There is a trend
increase in utility for patients not developing SSI and a
non-significant trend decrease for patients with SSI
between baseline and day 30 (P = 0.236). Differences
between the two groups are not statistically significant at
any timepoint. Model coefficients are displayed in Sup-
plementary Table S4.
3.4 | Readmissions
The number of patients readmitted to hospital within
30 days of the index procedure and the number of
patients who returned to work within 90 days are shown
in Table 4. Patients with SSI had relative odds of 4.39
(95% CI; 1.30-14.86) to be readmitted to hospital com-
pared with patients without SSI (21% readmitted vs 6%,
respectively).
3.5 | Return to work
Patients with SSI had relative odds of 0.12 (95% CI;
0.03-0.55) for return to work within 90 days of the index
procedure compared to those who did not have SSI (8%
returned to work vs 43%, respectively) (Table 4). The
mean number of days until return to work, conditional
on returning to work, for a patient without SSI was 16.58
(95% CI 12.54-20.62) compared with 25.5 (95% CI
16.68-34.32) for a patient with SSI. Because only two
patients in the infection group returned to work within
the study period, it was not possible to perform any statis-
tical analysis to compare the two groups.
4 | DISCUSSION
This study provides insight into the clinical and economic
burden associated with SSI in one large NHS teaching
hospital. In a sample of 136 patients undergoing vascular
surgery, 21% developed SSI which was associated with a
mean increase in LOS of 9.72 days and an average cost of
£3776 per episode. These results are consistent with pre-
vious studies9,10 but we note that previous studies did not
control for potential confounding variables, and for this
reason the present study may provide a more robust esti-
mate of the impact of SSI on length of stay. In this study
population, age and the type of vascular procedure were
found to be significantly associated with length of stay,
but conversely smoking status, BMI, and the presence of
diabetes were not. After adjusting for potential con-
founding factors SSI is still associated with a more than
90% increase in length of stay (on the untransformed
scale).
This study has also highlighted the importance of
antibiotic costs which are often overlooked. The main
driver of cost for most patients is prolonged LOS. How-
ever, for a minority of patients, antibiotic costs are the
most significant component. In the present sample, 18%
of patients (five patients) accounted for more than 90% of
antibiotic costs, and two patients had costs in excess of
£4000. High-cost patients are likely to be those with a
resistant infection, or those with a deep infection involv-
ing a prosthetic graft, who may have been unsuitable for
explanation, which in itself would be a costly surgical
procedure. Previous studies have demonstrated that
antibiotic-resistant SSIs, and antibiotic resistance gener-
ally, can add considerable treatment costs.20-22
The odds of readmission in the SSI group were
higher, and the development of SSI was shown to poten-
tially lead to a reduction in the rate of return to work. Of
the patients who did not develop SSI, 6% were readmitted
and 44% returned to work within 90 days compared with
21% readmitted and 8% returned to work for patients
with SSI. In principle delayed return to work would
impose social costs in terms of lost productivity.23,24
However, in the present sample because of the average
TABLE 4 Number of patients readmitted to hospital or
returned to work
Readmitted to hospital within 30 days
No readmission Readmission
No infection (n = 107) 101 6
Infection (n = 29) 23 6





No infection (n = 60) 34 26
Infection (n = 24) 22 2
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age of the patients (63 or 64 years) many would not be
expected to be working in any case.
The analysis here relates solely to costs incurred in
the hospital for infections diagnosed before discharge, or
for infections requiring readmission. Many surgical infec-
tions are diagnosed after discharge and managed in the
community, and for this reason the estimates here do not
represent the overall impact of SSI on the NHS. It is esti-
mated that approximately 11% of the costs of SSI fall on
the community or on the patient.25 Future studies might
capture the true cost impact by linking primary care
records in the Clinical Practice Research Datalink
(CPRD) database with Hospital Episode Statistics (HES)
in order to trace the impact on both secondary and pri-
mary care services.
The presence of SSI was associated with a reduction
of 0.156 at day 30 (P = 0.236) in patient-reported health-
state utility measured by EQ-5D-3L compared to the no
SSI group. Utility declined over time for patients with SSI
in contrast to other patients whose utility increased but
these trends were not statistically significant. The study
was not powered to detect differences in HRQoL and the
number of complete records was limited. A previous sys-
tematic review of the literature concluded that SSI has a
clinically significant impact on health-state utility and
HRQoL.26 Three patient-level studies27-29 reported EQ-
5D utility values associated with SSI, with a utility decre-
ment ranging from 0.102 to 0.124.
This study adds to the current evidence base showing
a substantial impact of SSI on patients and on healthcare
systems and provides fresh insight into the impact of SSI
within vascular surgery. The overall SSI rate in this study
is in line with SSI incidence quoted in the literature.2-4
While there is a significant financial cost associated with
an increase in LOS, this also puts patients at an increased
risk of further complications, such as longer overall
recovery times and further non-SSI infections including
respiratory and urinary tract infections.30 Other conse-
quences of prolonged hospital stay include pressure-
related skin damage, venous thromboembolism,
deconditioning and an increase in frailty, and ultimately
an increase in mortality. At an institutional level, delayed
discharge and higher readmissions limit the availability
of beds and theatre resources, lengthen waiting lists and
delay admissions from the emergency department, poten-
tially severely impacting care.
On an individual basis, SSI may have devastating con-
sequences, impacting on both the physical and mental
health of patients during their inpatient stay and follow-
ing discharge.7 Physical disability and symptoms of
depression have been shown to be related, and up to half
of patients with depression during hospitalisation have
been shown to remain depressed at 6 months post-
discharge.31 The effect of SSI on mental and physical
health may produce further, unmeasured financial costs
to both the patient and healthcare services in terms of
additional treatments required for indirect and direct
consequences of developing infection.
In conclusion, the results of this analysis and other
studies indicate that SSI has a considerable cost impact
for hospital providers through increased length of stay,
readmission and the costs of antibiotics. Existing strate-
gies to reduce the risk of SSI are not benefitting high-risk
vascular patients and future interventions should there-
fore be investigated in detail. These interventions should
be explored with robust, well-conducted clinical trials.
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